GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2006

IntelliGeneScan Gained License to a Biomarker Panel for Colorectal Cancer

  • IntelliGeneScan (IGS) obtained exclusive rights to develop and commercialize a colon cancer diagnostic test based on a biomarker panel discovered at the California Pacific Medical Center (CPMC). The test is minimally invasive, highly accurate, and less expensive than methods currently used in medical practice, reports CPMC.

    CPMC says it chose IGS for its market focus and resource strength. In exchange for the license rights, CPMC received an upfront payment and is eligible to receive milestone fees and royalties on sales of products covered by this agreement. IGS also provided CPMC with funding for a research program to expand upon the clinical tests, which led to the initial discovery. Both CPMC and IGS expect the results of this program will confirm the findings of the first battery of tests and also lead to enhancements in its detection processes.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?